Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869499 | 1.00 | ALOX5 (0.52) | ALOX5MAOBACACBFFAR1LMNA | |
| SCHEMBL3882627 | 0.89 | LTA4H (0.50) | ALOX5ACACBLMNAL3MBTL1LTA4H | |
| SCHEMBL3882630 | 0.89 | LTA4H (0.50) | ALOX5ACACBLMNAL3MBTL1LTA4H | |
| SCHEMBL4000090 | 0.89 | LTA4H (0.50) | ALOX5ACACBLMNAL3MBTL1LTA4H | |
| SCHEMBL3719114 | 0.78 | FFAR1 (0.60) | ALOX5MAOBACACBFFAR1LTA4H | |
| SCHEMBL28142532 | 0.78 | FFAR1 (0.60) | ALOX5MAOBACACBFFAR1LTA4H | |
| SCHEMBL3719120 | 0.78 | FFAR1 (0.60) | ALOX5MAOBACACBFFAR1LTA4H | |
| SCHEMBL2885897 | 0.78 | ALOX5 (0.62) | ALOX5MAOBACACBFFAR1LMNA | |
| SCHEMBL3877765 | 0.77 | ESR1 (0.41) | LMNA | |
| SCHEMBL3877776 | 0.77 | ESR1 (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139843-B1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ALOX5 998/4885MAOB 2736/4885ACACB 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.